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Systemic infection triggers a spectrum of metabolic and behavioral changes, collectively termed sickness behavior, which
while adaptive, can affect mood and cognition. In vulnerable individuals, acute illness can also produce profound, maladap-
tive, cognitive dysfunction including delirium, but our understanding of delirium pathophysiology remains limited. Here, we
used bacterial lipopolysaccharide (LPS) in female C57BL/6J mice and acute hip fracture in humans to address whether dis-
rupted energy metabolism contributes to inflammation-induced behavioral and cognitive changes. LPS (250 mg/kg) induced
hypoglycemia, which was mimicked by interleukin (IL)-1b (25 mg/kg) but not prevented in IL-1RI2/2 mice, nor by IL-1 re-
ceptor antagonist (IL-1RA; 10mg/kg). LPS suppression of locomotor activity correlated with blood glucose concentrations,
was mitigated by exogenous glucose (2 g/kg), and was exacerbated by 2-deoxyglucose (2-DG) glycolytic inhibition, despite
preventing IL-1b synthesis. Using the ME7 model of chronic neurodegeneration in female mice, to examine vulnerability of
the diseased brain to acute stressors, we showed that LPS (100 mg/kg) produced acute cognitive dysfunction, selectively in
those animals. These acute cognitive impairments were mimicked by insulin (11.5 IU/kg) and mitigated by glucose, demon-
strating that acutely reduced glucose metabolism impairs cognition selectively in the vulnerable brain. To test whether these
acute changes might predict altered carbohydrate metabolism during delirium, we assessed glycolytic metabolite levels in CSF
in humans during inflammatory trauma-induced delirium. Hip fracture patients showed elevated CSF lactate and pyruvate
during delirium, consistent with acutely altered brain energy metabolism. Collectively, the data suggest that disruption of
energy metabolism drives behavioral and cognitive consequences of acute systemic inflammation.
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Significance Statement
Acute systemic inflammation alters behavior and produces disproportionate effects, such as delirium, in vulnerable individuals.
Delirium has serious short and long-term sequelae but mechanisms remain unclear. Here, we show that both LPS and interleu-
kin (IL)-1b trigger hypoglycemia, reduce CSF glucose, and suppress spontaneous activity. Exogenous glucose mitigates these
outcomes. Equivalent hypoglycemia, induced by lipopolysaccharide (LPS) or insulin, was sufficient to trigger cognitive impair-
ment selectively in animals with existing neurodegeneration and glucose also mitigated those impairments. Patient CSF from
inflammatory trauma-induced delirium also shows altered brain carbohydrate metabolism. The data suggest that the degenerat-
ing brain is exquisitely sensitive to acute behavioral and cognitive consequences of disrupted energy metabolism. Thus “bioener-
getic stress” drives systemic inflammation-induced dysfunction. Elucidating this may offer routes to mitigating delirium.
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Introduction
Systemic infection triggers a spectrum of metabolic and behav-
ioral changes, termed sickness behavior, which includes fever,
lethargy, hypophagia, anhedonia. Sickness behavior is an evolu-
tionarily conserved response to illness and represents a repriori-
tization by the organism to conserve energy and maximize the
probability of recovery (Dantzer, 2004). Systemic administration
of the bacterial endotoxin lipopolysaccharide (LPS) can induce
sickness behavior in humans (Schedlowski et al., 2014; Draper et
al., 2018) and rodents (Teeling et al., 2007; Carlton and Demas,
2017) and despite not readily crossing the blood-brain barrier
(Banks and Robinson, 2010), LPS increases central proinflamma-
tory cytokines including interleukin (IL)-1b and tumor necrosis
factor (TNF)-a (Teeling et al., 2007; Murray et al., 2011; Skelly et
al., 2013), and alters local field potential (Semmler et al., 2008;
Mamad et al., 2018). Peripheral inflammatory status is commu-
nicated to the brain via direct vagal signaling to the brainstem
and hypothalamus; macrophage activation in the circumventric-
ular organs lacking a patent BBB, leading to secretion of inflam-
matory mediators into the parenchyma; and activation of
endothelial cyclooxygenases to secrete lipophilic prostaglandins
directly into the parenchyma (Dantzer, 2018). Manipulation of
prostaglandin-dependent mechanisms revealed neuroanatomical
pathways underpinning sickness responses (Saper et al., 2012),
but the molecular basis for acute LPS-induced suppression of ac-
tivity is poorly understood.
Sickness behavior sometimes encompasses cognitive impair-
ment: peripheral LPS or IL-1b administration can affect synaptic
plasticity and hippocampal-dependent learning and memory
(Yirmiya and Goshen, 2011), although the relative preservation of
cognitive function is striking given the overt suppression of spon-
taneous behavior (Cunningham and Sanderson, 2008; Skelly et al.,
2019). However, when inflammatory insults are severe, or occur
in older age or during evolving dementia, they may induce delir-
ium (Elie et al., 1998). Delirium is an acute onset and fluctuating
syndrome characterized by inability to sustain attention, reduced
awareness and perception, and profound cognitive impairment
(American Psychiatric Association, 2013), affecting ;1/5 hospital
inpatients (or 1/3 for those .80 years age; Ryan et al., 2013).
Delirium is associated with extended hospitalization, subsequent
cognitive decline, and increased risk for dementia, but the neuro-
biological understanding of delirium is limited.
We have modeled delirium, using superimposition of LPS on
models of neurodegeneration (Field et al., 2012; Murray et al.,
2012; Cunningham and Maclullich, 2013; Lopez-Rodriguez et al.,
2018) to produce acute onset, fluctuating deficits in relevant cog-
nitive domains (Davis et al., 2015). These LPS-associated deficits
are absent in normal animals but susceptibility to LPS-induced
cognitive impairment increases as a function of the underlying
neurodegenerative state of the brain (Griffin et al., 2013; Davis et
al., 2015). LPS-induced deficits are prostaglandin dependent and
can be mimicked by systemic administration of IL-1b (Griffin et
al., 2013) or TNF-a (Hennessy et al., 2017) and reduced by sys-
temic administration of IL-1 receptor antagonist (IL-1RA;
Cunningham and Sanderson, 2008; Skelly et al., 2019), suggest-
ing that IL-1b may affect cognition via a peripheral route. One
possibility is that acute sickness impinges on cerebral metabolism
through systemic metabolic changes; cerebral glucose uptake is
reduced in a rat model of LPS-induced sepsis (Semmler et al.,
2008), carbohydrate metabolism is decreased post-LPS (Irahara
et al., 2018), and IL-1 has been demonstrated to induce hypogly-
cemia (Del Rey et al., 2006). Systemic hypoglycemia impacts on
central glucose levels (Kealy et al., 2015), which in turn can affect
neuronal activity and may be especially detrimental if the
brain is already compromised during evolving neurodege-
nerative pathology.
Therefore, we hypothesized that LPS-induced disturbances in
glucose metabolism would drive suppression of activity and cog-
nitive impairment in mice. We assessed locomotor activity and
working memory, while manipulating glucose metabolism with
LPS, 2-deoxyglucose (2-DG), and insulin to determine effects of
altered glycemic status on sickness behavior and cognitive
impairments in disease-naive and ME7 mice. Finally, we ana-
lyzed carbohydrate metabolism in the cerebrospinal fluid (CSF)
of inflammatory trauma (hip fracture) patients to assess brain
energy metabolites in humans with inflammation-induced delir-
ium. The findings show that altered glycemic status causes dis-
ruption of brain function in mice and that brain carbohydrate
metabolism is also disrupted during delirium in patients.
Materials and Methods
Animals
Female c57BL/6J aged five to eight months (Harlan), mixed sex IL-
1R1/ mice (sixmonths) and mixed sex c57BL/6J aged 8–12weeks (in-
house colony) were housed at 21°C with a 12/12 h light/dark cycle (lights
on 8 A.M. to 8 P.M.) with food and water available ad libitum. All animal
experiments were in accordance with European Commission Directive
2010/63/EU and were performed following ethical approval by the TCD
Animal Research Ethics Committee and licensing by the Health
Products Regulatory Authority (HPRA).
ME7 prion model of neurodegeneration
Mice were anaesthetized using Avertin (2,2,2-tribromoethanol 50% w/v
in tertiary amyl alcohol, diluted 1:40 in H2O; 20 ml/kg, i.p.; Sigma) and
placed in a stereotaxic frame (David Kopf Instruments). A total of 1ml
of 10% w/v ME7-infected c57BL/6J or 10% w/v normal brain homoge-
nate (NBH) in sterile PBS was infused into the dorsal hippocampus at
2.0 mm (A/P), 61.6 mm (M/L), 1.7 mm (D/V) from Bregma as
described previously (Murray et al., 2011, 2012). Mice recovered in a
heated chamber, then returned to their home cage where their drinking
water was supplemented with sucrose (5% w/v) and carprofen (0.05% v/
v; Rimadyl, Pfizer).
Treatments
Mice were injected intraperitoneally with one or a combination of the
following treatments using sterile saline as a vehicle: LPS from
Salmonella equine abortus (100 or 250mg/kg; Sigma), IL-1b (25mg/kg;
R&D Systems), IL-1RA (10mg/kg; Kineret, Biovitrum), glucose (2 g/kg;
Sigma), 2-DG (2 g/kg; Sigma), and insulin [11.5 IU/kg (400mg/kg);
Sigma]. LPS was administered 2 h before open field behavior (Except
where noted as 5 hours) and 3 h before the T-maze task. Glucose was
administered 30min before any behavioral task.
Body temperature
Body temperature was measured in mixed sex c57BL/6J (8–12weeks
old) by subcutaneous transponders (IPTT300; BioMedic Data Systems)
that were implanted under isoflurane using a custom-designed injector.
The temperature was checked every 20min with BMDS Smart Probes
7000 series Reader (BioMedic Data Systems) starting from 1 h before the
saline or LPS challenge up to 240min after the treatment.
Behavioral assessment
Spontaneous activity was assessed by observing locomotor activity in an
open field as previously described (Murray et al., 2013). Briefly, mice
were allowed to freely and individually explore an open field arena
(58 33  19 cm), which was divided into squares (10 10 cm). Over
the course of 3min, the number of squares crossed by each mouse was
counted.
Cognitive performance was assessed using an escape-from-water
alternation task in a paddling T-maze as described previously (Murray et
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al., 2012; Skelly et al., 2019). Briefly, this working memory task involves
two runs per trial. On the first run, mice only have one of the T-maze
arms available to them, which has an exit at the end of it to escape from
the shallow water. On the second run, mice are given a choice between
the two arms with the exit now in the opposite arm to the first run. Mice
were trained (two blocks/day, five trials/block, two runs/trial) until they
performed with at 80% success. They were then pharmacologically
challenged and tested on the same day of the challenge. There were three
blocks of five trials postchallenge [corresponding to 3–5 (13), 5–7 (15),
and 7–9 (17) h postchallenge] and two blocks for insulin, due to its
rapid action on blood glucose [corresponding to 40–160min (11 h) and
160–300min (13 h) postchallenge]. All mice underwent recovery testing
(two blocks of five trials) on the following day.
Blood glucose measurements
For serial blood measurements, mice were placed in a plastic restrainer,
the tail vein was dilated using warm water and lanced using a 30-G nee-
dle. Glucose was measured using a veterinary glucometer (AlphaTRAK
2, Zoetis), which assesses glucose concentration based on oxidation by
flavin adenine dinucleotide (FAD) glucose dehydrogenase. This enzyme
preferentially accepts glucose as substrate but shows 2-DG oxidation at
37% of the rate of glucose oxidation. However, at a dose 0.0003 mol 2-
DG/25-g mouse, this 2-DG is insufficient to affect blood glucose (;10
mM) determination. Terminal blood glucose measurements were made
following sodium pentobarbital overdose and incising the right ventricle,
immediately before transcardial perfusion. Blood glucose readings were
higher on the veterinary glucometer compared with a clinical glucometer
(data not shown), but basal levels were broadly in line with other studies
(Del Rey et al., 2006, 2016; Chakera et al., 2018; Tooke et al., 2019).
CSF sampling and analysis
In mice, CSF was collected under terminal anesthesia. Mice were placed
in a stereotaxic frame and the cisterna magna accessed by lowering the
incisor bar on the animal’s head to angle it downwards at 45° from hori-
zontal. Using a small volume insulin syringe (BD Micro - Fine1 0.3 ml
Insulin Syringe Demi), a freehand puncture was performed slowly to
avoid brain stem damage and blood contamination. Approximately 5ml
was collected in 0.5-ml microcentrifuge tubes.
Hip fracture patient cohort
Hip fracture is a frequent occurrence in frail, elderly populations.
Delirium occurs with high prevalence in these patients (Marcantonio,
2017), and since these patients, in many centers, receive spinal anesthesia
for hip fracture repair surgery, this offers an opportunity for CSF collec-
tion allowing assessment of the impact of this acute inflammatory
trauma on CSF markers of brain energy metabolism in older individuals.
CSF was collected from hip fracture patients acutely admitted to Oslo
University Hospital after informed consent from the patient and/or
proxy (if patients were unable to consent due to cognitive impairment),
as approved by the Regional Committee for Medical and Health
Research Ethics (South-East Norway; REK 2009/450). The presence of
delirium was assessed in all participants using the Confusion
Assessment Method (CAM; Inouye et al., 1990) based on a 10- to 30-
min interview with participants and information from relatives, nurses,
and hospital records. One geriatrician and one old age psychiatrist inde-
pendently evaluated whether participants met the ICD-10 criteria for de-
mentia before the fracture, based on all available data, as explained
earlier (Watne et al., 2014b). CSF was collected in propylene tubes at the
onset of spinal anesthesia. Samples were centrifuged, aliquoted and
stored at –80°C, as previously described (Watne et al., 2014a).
Samples were defrosted and transferred to CMA Microvials (CMA
Microdialysis AB). In mice, there were two occasions where sample vol-
umes were too small (,3ml) for analysis. In these cases, two samples
from the same treatment groups were pooled (see Fig. 2H,I). All other
mouse CSF measurements were made on samples taken from individual
mice. Glucose, lactate, and pyruvate (the latter in humans only) concen-
trations were determined using a CMA600 Microdialysis Analyzer
(CMA Microdialysis AB). The CMA600 uses a colorimetric analysis
technique to detect these analytes. Using glucose as an example, the
CMA reagent works by metabolism of glucose by glucose oxidase to
form its gluconic acid and hydrogen peroxide. The hydrogen peroxide
then reacts with phenol to produce a color change and this is detected by
a photometric sensor. While 2-DG (used as a treatment in some mice
that undergo this analysis) can react with glucose oxidase, its reactivity is
much lower than that of glucose (Vmax around 50 vs glucose 1150 M s
1;
Gibson et al., 1964). In practice, 2-DG treatment has no significant effect
on CSF glucose readings based on our data (see Fig. 2K). Basal levels of
CSF glucose were in the range expected from other studies (Horn and
Klein, 2010; Nakamura et al., 2017; Tang et al., 2017), as was the case for
CSF lactate (Horn and Klein, 2010). The lower limits of detection were:
glucose (0.1mmol/l), lactate (0.1mmol/l), and pyruvate (4mmol/l).
Since the ability to detect pyruvate is an indication of its concentration,
non-detected samples probably represent very low concentrations of py-
ruvate. However, samples where no value was returned by the assay
were assigned the value of 2mmol/l (i.e., 50% of the lowest value that we
did detect) as a conservative measure.
Experimental design and statistical analyses
Statistical analysis was performed in GraphPad Prism 5 and IBM SPSS
version 25. Pairs of groups were measured using t tests, and all multiple
comparisons were made using ANOVAs, paired and repeated measure
variants were used as appropriate. Full statistical analyses and experi-
mental numbers are included in figure legends. Where data were found
to violate the assumptions of t tests (using a combination of visual
inspection, Kolmogorov–Smirnov and the Shapiro–Wilk normality
tests), the non-parametric Mann–Whitney U test was used instead. The
group numbers, statistical tests used, and test values are all summarized
in Table 1.
Results
LPS and IL-1b both robustly reduce systemic glucose
concentrations
The effects of systemic infection on spontaneous activity have
largely been attributed to changes in cytokine signaling (Dantzer,
2018). IL-1 is reported to act at the endothelium or at forebrain
targets to mediate LPS-induced suppression of motivated behav-
iors (Liu et al., 2019), but precisely how suppression of explora-
tory activity occurs is unclear. Here, we examined LPS-induced
suppression of activity (see Fig. 1A) and confirmed that LPS
(250mg/kg, i.p.) significantly increased plasma IL-1b levels at 2
and 6 h postchallenge in c57BL/6J mice compared with saline-
treated controls (Fig. 1B) and also reduced blood glucose levels
by .50% by 7 h postchallenge (Fig. 1C). Blood glucose was
decreased as early as 3 h following LPS and had not fully
returned to baseline levels by 24 h. This reduction is not
explained by suppression of feeding since blood glucose declines
rapidly here (Fig. 1B,E) but only begins to decrease after 6–12 h
of fasting in healthy c57BL/6J mice (Champy et al., 2004).
We investigated the contribution of IL-1b signaling to LPS-
induced hypoglycemia. IL-1b (25mg/kg, i.p.) reduced blood glu-
cose, with a more rapid induction and earlier nadir than LPS
(Fig. 1D). IL-1b -induced reductions in glucose were completely
blocked by IL-1RA (10mg/kg i.p.). Therefore, IL-1b is sufficient
to reduce systemic glucose levels.
To test whether IL-1b is necessary for LPS-induced hypogly-
cemia, we administered LPS (250mg/kg, i.p.) and IL-1b (25mg/
kg, i.p.) to IL-1 receptor-1 knock-out (IL-1R1/) mice and
c57BL/6J wild-type (WT) controls. Blood glucose measurements
were taken 4 h postchallenge, to ensure robustly decreased glu-
cose (Fig. 1C,D). LPS and IL-1b again reduced blood glucose in
WT mice. Although IL-1b -induced hypoglycemia was pre-
vented in IL-1R1/ mice, LPS-induced reductions in glucose
were statistically indistinguishable from those in WTs (Fig. 1E).
Moreover, the time course of LPS-induced glucose reduction was
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Table 1. Summary of experimental design and statistical analyses used in this study
Figure Group (n) Test used Statistical values p value Post hoc tests
1B c57BL6 mice:
Saline at 2 h (8)
Saline at 4 h (6)
LPS at 2 h (6)
LPS at 4 h (6)












LPS vs saline at 2 h:
t= 6.215; p, 0.001
LPS vs saline at 4 h:
















LPS vs saline at 5 h:
t= 3.362; p, 0.01
LPS vs saline at 7 h:

















IL-1b1Sal vs Sal1Sal 1 h:
t= 3.566; p, 0.01
IL-1b1Sal vs Sal1Sal 3 h:
t= 3.409; p, 0.01
IL-1b1Sal v IL-1b1IL-1RA 3 h: t= 3.013;
p, 0.05




















IL-1b – c57BL6 v IL-1R1/
t= 2.836; p, 0.05
Within genotypes:
c57BL6 – LPS vs Sal
t= 4.287; p, 0.001
c57BL6 – IL-1b vs Sal
t= 2.465; p, 0.05
IL-1R1/ – LPS vs Sal
t= 4.763; p, 0.001
1F LPS in WT, IL-1R1/
c57BL61LPS (7)
IL-1R1/1LPS (5)































LPS1Sal vs Sal1Sal 2 h
t= 3.449; p, 0.01
LPS1Sal vs Sal1Sal 4 h
t= 5.160; p, 0.001
LPS1Sal vs Sal1Sal 6 h
t= 4.319; p, 0.001
LPS1IL-1RA vs Sal1Sal 4 h: t= 4.551; p, 0.001














LPS vs Sal at 4 h
t= 3.576; p, 0.050
LPS vs Sal at 7 h




14  2 repeated
measures ANOVA





















LPS vs Sal at 5 h













LPS vs Sal at 5 h
t= 3.122; p, 0.05
(Table continues.)
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Table 1 Continued




Linear regression Saline: slope = 3.512 6 7.51; r2 =
0.01790




















Spontaneous: LPS vs Sal
t= 3.457; p, 0.01
Within treatments:
LPS (Spont. vs prompt)
t= 7.060; p, 0.001
LPS (Spont. vs total)



















t= 3.580; p, 0.01
Sal1glucose vs LPS1glucose

























t= 4.813; p, 0.001
LPS1Sal vs LPS1glucose

























t= 6.010; p, 0.001
Sal1Gluc. vs LPS1Gluc.
t= 4.931; p, 0.001
LPS1Sal vs LPS1glucose























LPS1Sal vs LPS1glucose:2 h
t= 6.784; p, 0.001
Within treatments:
LPS1glucose, –1 vs 2 h



















t= 4.235; p, 0.001
Sal1glucose vs LPS1glucose
t= 4.720; p, 0.001
Sal1Sal vs Sal1glucose
t= 2.795; p, 0.05
LPS1Sal vs LPS1glucose






t(7) = 3.367 0.0120
(Table continues.)
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Table 1 Continued



















































3 h: t= 2.608; p, 0.05
ME71Sal vs ME71LPS: 5 h: t= 4.933; p, 0.001
ME71Sal vs ME71LPS






















t= 3.829; p, 0.01
NBH1Sal vs NBH1insulin180
t= 3.447; p, 0.01
ME71Sal vs ME71insulin90
t= 3.756; p, 0.01
ME71Sal vs ME71insulin180






















t= 4.691; p, 0.001
ME71Sal vs ME71insulin90




















ME71Sal v ME71insulin:1 h
t= 3.235; p, 0.01
ME71Sal v ME71insulin: 3 h



















t= 7.011; p, 0.001
ME71saline vs ME71LPS



















t= 6.910; p, 0.001
ME71Sal vs ME71LPS
t= 10.39; p, 0.001
NBH1Sal vs ME71Sal


















No post hocs performed
(Table continues.)
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highly overlapping in WT and IL-1RI/ mice (Fig. 1F). IL-1b
antagonism with IL-1RA has been reported to attenuate LPS-
induced hypoglycemia (Del Rey et al., 2006). Here, IL-1RA
(10mg/kg) showed only a very modest and temporary protective
effect against 250mg/kg LPS-induced decreases in glucose 2 h
postchallenge and no effect thereafter, as detailed in Figure 1G.
Therefore, systemic IL-1b is sufficient to lower blood glucose,
but it is not indispensable for LPS-induced decreases in glucose.
Blood glucose concentration is a major determinant of LPS-
induced acute hypoactivity
IL-1b has been reported as the major driver of sickness behavior
(Matsuwaki et al., 2017; Dantzer, 2018). We sought to understand
whether IL-1b signaling or decreases in glucose might be the prox-
imate cause of LPS-induced hypoactivity. We first showed that
LPS, at 250mg/kg, intraperitoneally, produces an acute decrease in
blood glucose, emerging from;2 h and statistically significant at 4
h (p=0.0206) and 7 h (p=0.0074), that temporally overlaps with
acute suppression of locomotor activity (p=0.0207) and rearing
behavior (p=0.0062). This hypoglycemia and inactivity are not
occurring in the context of elevated body temperature, which does
not change significantly during this period (Fig. 2).
LPS-induced hypoactivity in c57BL/6J mice (squares crossed/
3min) was significantly positively correlated with blood glucose
levels (Fig. 3A), with low blood glucose predicting low activity in
LPS-treated mice (r2 = 0.4824, p=0.002), while no significant
correlation was present between blood glucose and activity in sa-
line-treated animals. In a separate experiment, LPS-treated mice
showed significantly less spontaneous activity in the open field
compared with saline-treated controls but when inactive mice
were prompted to move, using a gentle finger nudge, similar lev-
els of activity were observed in both groups (Fig. 3B) demon-
strating that these animals are not unable to move or prevented
from moving due to reduced energy availability. Rather, LPS-
induced hypoactivity (Fig. 3A) reflects reduced spontaneous ac-
tivity. Moreover, the changes in blood glucose and activity are
not dependent on changes in body temperature since parallel
experiments (Fig. 2B) demonstrated that body temperature was
not significantly elevated under these conditions.
We then hypothesized that LPS-induced hypoactivity would
be mitigated by treatment with glucose (2 g/kg, i.p.). In our ex-
perimental design (Fig. 3C), we also included a separate group of
mice that received LPS12-DG, which inhibits glucose-6-phos-
phate isomerase to prevent glycolysis, which in turn blocks mac-
rophage synthesis of IL-1b (Tannahill et al., 2013). LPS robustly
produced IL-1b , reduced blood and CSF glucose levels, and sup-
pressed activity (Fig. 3D–H). Glucose treatment had no effect on
IL-1b production (Fig. 3D) but significantly improved locomo-
tor activity (Fig. 3E) and increased circulating glucose concentra-
tion (Fig. 3F). Administering glucose to mice, following LPS
treatment, only transiently protected against LPS-induced
decreases in blood glucose levels (Fig. 3G) as has previously been
shown (Del Rey et al., 2006). In CSF, LPS significantly reduced
Table 1 Continued
Figure Group (n) Test used Statistical values p value Post hoc tests



















3 h: LPS1Sal vs Sal1Sal
t= 4.230; p, 0.001
5 h: LPS1Sal vs Sal1Sal
t= 6.426; p, 0.001
5 h: LPS1glucose vs LPS1sal
t= 3.543; p, 0.01
5 h: Sal1glucose vs LPS1glucose
t= 2.826; p, 0.05










test, a priori one-
tailed
U= 442.5 0.0128











































t= 4.580; p, 0.001
ME71saline vs ME71LPS
t= 4.887; p, 0.001
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glucose concentrations, and similar to the periphery, glucose treat-
ment significantly protected against this (Fig. 3H). However, CSF
lactate remained statistically unchanged in all groups (Fig. 3I).
Therefore, LPS reduces CSF glucose concentration by ;50%, and
this can be mitigated by systemic glucose administration, with
concomitant rescue of spontaneous activity. As predicted, 2-DG
blocked LPS-induced IL-1b secretion (Fig. 3D), and yet hypoac-
tivity remained striking (Fig. 3E). Therefore, animals with high IL-
1b can remain spontaneously active if glucose concentration is
temporarily boosted, and despite LPS producing no IL-1b when
animals were additionally exposed to an inhibitor of glycolysis,
these 2-DG-treated LPS animals show even less locomotor activity.
These findings were replicated in a separate cohort of mice using a
separate batch of LPS (100mg/kg; i.p.; data not shown).
While 2-DG had a significant effect on spontaneous activity
and blood glucose in LPS-treated mice, 2-DG on its own only
modestly reduced locomotor activity (Fig. 3J), and this decrease
was not statistically significant (t=1.894; df = 27, p=0.069) in
this normally distributed dataset. Likewise, 2-DG had no signifi-
cant impact on blood glucose concentrations (Mann–Whitney,
U= 74.00; p= 0.1951). However, these data were not normally
distributed (failed 2/3 normality tests), and a small number of
samples showed higher levels (Fig. 3K). On subjective examina-
tion, mice receiving 2-DG alone did not appear sick but those
showing the lowest activity post-2-DG tended to be those show-
ing the highest levels of glucose, perhaps suggesting that blocking
glucose utilization (functionally similar to hypoglycemia) could
increase blood glucose but still produce inactivity as has been
shown with higher doses of 2-DG (Voss et al., 2018).
Collectively, the data demonstrate that reduced glucose me-
tabolism is a key proximate cause of LPS-induced suppression of
spontaneous activity.
Figure 1. LPS and IL-1b significantly lower blood glucose concentrations. A, Timeline for treatments and sampling times. Blood sampling was from tail vein, aside from the 24 hours (h)
time point where glucose levels were measured from right atrial blood before transcardial perfusion. In one cohort, mice were euthanized at 2 and 6 h post-LPS challenge to collect plasma for
the IL-1b Enzyme linked immunoabsorbent assay (ELISA). B, LPS treatment (250mg/kg, i.p.) significantly increased plasma IL-1b (F(1,22) = 36.71; p, 0.0001; n= 8 for saline/2 h group;
n= 6 for other groups). C, LPS treatment (n= 7) significantly reduced glucose levels over 24 h compared with saline controls (0.9%, i.p.; n= 6); main effect of treatment (F(1,44) = 24.10;
p= 0.0005). D, IL-1b (25mg/kg, i.p.; n= 7) reduced systemic glucose and IL-1b ’s effect can be blocked using IL-1RA (10 mg/kg, i.p.; n= 7). Main effect of treatment (F(2,85) = 3.843;
p= 0.0420); **significantly lower glucose levels in IL-1b1saline-treated mice compared with controls (n= 6) at 1 and 3 h postchallenge. E, c57BL/6J mice, both LPS (n= 6) and IL-1b
(n= 5) significantly reduced blood glucose 4 h postchallenge versus saline controls (n= 6), while in IL-1R1/ mice, LPS (n= 6) but not IL-1 (n= 6) significantly reduced blood glucose versus
controls (n= 6). Significant pairwise comparisons by Bonferroni post hoc test after a main effect of treatment (F(2,29) = 21.81; p, 0.0001) are annotated by * (p, 0.05) and ***
(p, 0.001). F, Time course of changes in blood glucose in IL-1R1/ (n= 5) and c57BL/6J mice (n= 7; significant effect of genotype, F(1,40) = 5.673; p= 0.0385, but no pairwise differences
at any time point). G, IL-1RA (10 mg/kg, n= 12) administered immediately after LPS treatment modestly attenuated LPS-induced reductions in glucose (F(2,132) = 16.18; p, 0.0001), but this
was a transient effect (F(4,132) = 39.08; p, 0.001). There was a significant interaction of treatment and time (F(8,132) = 3.502; p= 0.0011), and post hoc tests indicated that LPS1saline-
treated mice (n= 12) had significantly lower blood glucose levels versus saline (n= 12) at 2, 4 and 6 h postchallenge, while LPS1IL-1RA (n= 12) did not significantly decrease glucose levels
compared with controls until 4 h. All annotated Bonferroni post hoc tests were performed after significant main effects or interactions in ANOVA analysis: *p, 0.05, **p, 0.01,
***p, 0.001. All data are expressed as mean6 standard error of the mean (SEM).
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Neurodegeneration increases susceptibility to cognitive
impairments due to reduced glucose availability
We have previously shown, using the ME7 model, that evolving
neurodegeneration progressively increases susceptibility to LPS-
induced transient working memory impairments on a T-maze
task (Murray et al., 2012; Skelly et al., 2019). We replicate this
here to illustrate the time course of these changes, and confirm
that LPS does not produce such deficits in normal animals (Fig.
4A). We hypothesized that this cognitive vulnerability in ME7
mice may be explained by a greater tendency toward metabolic
insufficiency and that cognitive function in ME7 mice might be
less able to cope with limiting glucose. We tested this hypothesis
using insulin (11.5 IU/kg, i.p.), which significantly lowered blood
glucose in both ME7 and NBH mice (Fig. 4B). Basal levels of in-
sulin were equivalent in ME7 and NBH mice, and all mice
showed similar insulin pharmacokinetics on insulin treatment
(Fig. 4C). Despite this, and analogous to LPS-induced cognitive
deficits (Fig. 4A), insulin induced significant acute working
memory dysfunction in ME7 mice that was absent in NBH con-
trols (Fig. 4D).
Given the ability of insulin-induced hypoglycemia to trigger
cognitive deficits selectively in mice with existing neurodegener-
ative disease (ME7), we examined whether LPS produced differ-
ential hypoglycemic responses in NBH and ME7 animals. Mice
were inoculated with ME7 or NBH and, 16weeks later, chal-
lenged with saline or LPS (100mg/kg, i.p.). LPS produced similar
glucose reductions in NBH and ME7 mice in both blood (Fig.
5A) and in CSF (Fig. 5B), although baseline CSF glucose con-
centration was slightly higher in ME7 animals with respect to
NBH. CSF lactate levels were similar in all four groups (Fig.
5C). Since ME7 and NBH mice showed
equivalent reduction in glucose, but dif-
ferential cognitive outcomes post-LPS
(Fig. 4A), and because LPS-induced
sickness behavior can be reversed by
intraperitoneal glucose (Fig. 3E), we
hypothesized that the LPS-induced cog-
nitive impairment in ME7 mice might
be mediated by limiting glucose supply/
utilization. ME7 mice were trained on
the “escape from water” T-maze, until
criterion performance of .80% correct
was achieved. They were then treated
with saline or LPS (100mg/kg, i.p.) and,
2.5 h after LPS, treated with saline or
glucose (2 g/kg, i.p.) before undergoing
T-maze testing. Neither saline-treated
nor glucose-treated ME7 mice deviated
from baseline T-maze performance in
the absence of LPS, but LPS-treated
ME7 mice showed robust impairment
between 3–7 h post-LPS. Those impair-
ments in ME71LPS1saline mice were
significantly attenuated by glucose applied
2.5 h after LPS (significant interaction of
treatment and time: F(12,240) = 3.740;
p, 0.0001; Fig. 5D). Bonferroni post hoc
analysis showed that ME71LPS1glucose
mice were significantly less impaired than
ME71LPS1saline mice at 5 h (p, 0.01).
Human delirium triggered by acute inflammatory trauma
(hip fracture) is associated with altered carbohydrate
metabolism
Acute inflammation disrupted glucose metabolism and this
caused acute cognitive dysfunction (Fig. 5). We have previously
demonstrated that this LPS-induced cognitive deficit is acute,
transient, and fluctuating, occurs only in animals with prior de-
generative pathology, and represents the best validated animal
model of delirium superimposed on dementia (Davis et al., 2015;
Schreuder et al., 2017). Therefore, seeking to investigate general-
izability of these findings from mice, we assessed CSF concentra-
tions of glycolytic metabolites in a cohort of acute hip fracture
patients admitted for hip fracture repair with spinal anesthesia
(for patient information, see Table 2). This represents an ideal
cohort because CSF sampling is possible at the time of spinal an-
esthesia and because delirium occurs in a significant subset of
these patients, and an acute inflammatory trauma (fracture) has
been the proximate trigger for this delirium (Hall et al., 2018).
Hip fracture patients with ongoing delirium at the time of
lumbar puncture (“prevalent delirium”) were compared with
those without any signs of delirium during hospital stay (preop-
eratively and postoperatively) on CSF glucose, lactate, and pyru-
vate (commonly used markers of central energy metabolism
disturbance in clinical populations; Leen et al., 2012; Zhang and
Natowicz, 2013). CSF glucose was not different in those with and
without delirium (Fig. 6A). A previous study of all-cause delir-
ium versus stable dementia (Caplan et al., 2010) provided the a
priori hypothesis that delirium would be associated with elevated
lactate, and lactate was indeed significantly elevated during
Figure 2. The impact of systemically applied LPS on blood glucose, body temperature and activity. A, Blood glucose.
Effect of systemic LPS on blood glucose levels from 60min before the challenge to 24 h after it. LPS (250mg/kg, i.p.; n= 8)
induced a significant decrease of blood glucose levels at 240 min (p= 0.0206) and 420 min (p= 0.007) when compared with
vehicle-treated (Vh) animals (n= 8). Main effect of treatment (F(1,14) = 9.74; p= 0.0075) and time (F(3,40) = 11.09). No dif-
ference was found at 24 h after LPS (p= 0.66). B, Body temperature. Effect of systemic LPS challenge (250mg/kg, i.p.;
n= 5) on body temperature as measured using subcutaneous temperature transponders. No differences were found when
compared with vehicle-treated (Vh) animals (n= 6). Main effect of time (F(3,24) = 5.166; p= 0.0082). C, Open field distance.
Effects of systemic LPS in the open field test. LPS (250mg/kg, i.p.; n= 8) significantly decreased the traveled distance at 5 h
(p, 0.0001) when compared with vehicle-treated (Vh) group (n= 12). Main effect of treatment (F(1,18) = 6.43; p= 0.0207)
and time (F(1,22) = 29.46; p, 0.0001). D, Open field rearing. Time spent rearing was significantly decreased by LPS
(250mg/kg, i.p.; n= 8) at 5 h (p= 0.0266) in comparison with vehicle-treated (Vh) mice (n= 12). Main effect of treatment
(F(1,15) = 10.11; p= 0.0062) and time (F(1,20) = 9.458; p= 0.0035). All annotated Bonferroni post hoc tests were performed
after significant main effects or interactions in ANOVA analysis: *p, 0.05. All data are expressed as mean6 SEM.
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delirium (one-tailed Mann–Whitney analysis; p= 0.0128; Fig.
6B). Changes in CSF lactate, associated with delirium, were not
explained by dementia status. That is, comparing all patients
with a diagnosis of dementia to all patients without dementia, in
an expanded cohort (see Table 2), revealed that lactate levels in
the CSF of hip fracture patients with dementia (n= 59), com-
pared with age-matched patients with no dementia (n= 55), were
not significantly different (U= 1438, p=0.2954; Fig. 6C). Median
pyruvate levels were significantly elevated in delirium (Fig. 6D).
Although pyruvate was not detectable in CSF of all patients, it
was detected significantly more often in patients with delirium
(Fig. 6E). The difference between delirium and no-delirium with
respect to frequency of pyruvate detection was found to be signif-
icant (p= 0.0306) using the Fisher’s exact test.
Increases in the CSF lactate:glucose ratio (LGR) have been
associated with reduced consciousness (Sanchez et al., 2013) and
increased mortality (Lozano et al., 2020), and here, these data
indicate an elevated LGR both in humans experiencing delirium
after acute inflammatory trauma (Fig. 6F) and in mice cogni-
tively impaired by acute systemic inflammation (Fig. 6G). The
changes in LGR observed in mice and humans differ in how they
arise, with an increase in the ratio driven by increases in lactate
in humans (Fig. 6A,B) and by decreases in glucose in the mouse
(Fig. 5A,C), but both mouse and human datasets indicate that
there is a significant derangement of brain energy metabolism
following these inflammatory insults, and in mice, this is clearly
causal for acute cognitive dysfunction.
Discussion
We demonstrate that LPS-induced hypoglycemia suppresses
spontaneous activity in mice. Glycemic status was a major deter-
minant of spontaneous activity after LPS. Reduced glucose avail-
ability also drove LPS-induced acute cognitive impairment in
mice with underlying neurodegeneration and impairments were
mitigated by exogenous glucose. The degenerating brain is also
selectively vulnerable to cognitive disruption by insulin, despite
equivalent blood glucose reductions. Finally, inflammatory
trauma-induced delirium in humans was associated with altered
central energy metabolism.
Figure 3. Low blood glucose concentration drives LPS-induced hypoactivity. A, Linear regression analyses of locomotor activity (squares crossed/3min) versus blood glucose concentration (mmol/l)
in animals challenged with saline (n=14) and LPS (n=17). Blood glucose concentrations significantly correlated with locomotor activity in LPS-treated mice. B, LPS significantly reduces spontaneous
activity in the open field compared with saline-treated controls. Prompting inactive mice to move by gently nudging them with a fingertip results in similar levels of activity, showing that LPS mice
are capable of moving but are not motivated to do so. C, Timeline for treatments and sampling times. Glucose (2 g/kg, i.p.) was administered 1.5 h post-LPS challenge (250mg/kg, i.p.), and open
field behavior was measured 2 h post-LPS challenge. Five minutes after open field testing, mice were euthanized, CSF samples taken, blood glucose levels assessed, and plasma collected for IL-1b
ELISA. In one group, 2-DG (2 g/kg, i.p.) was given 3 h before LPS. D, LPS (250mg/kg, i.p.; n=8) induced IL-1b production (F(1,25) = 29.88; p, 0.001), which was unaffected by glucose co-admin-
istration (n=7; 90min post-LPS) but blocked by 2-DG administration (intraperitoneal, n=5, #p=0.0296 vs LPS1saline). E, Locomotor activity was suppressed by LPS (main effect of LPS: F(1,27) =
13.39; p=0.0011) but rescued by glucose co-administration (interaction between treatments: F(1,27) = 10.48; p=0.0032); **significant difference between LPS1glucose (n=9) and LPS1saline
(n=8), and these were not significantly different to saline1saline (n=7) or saline1glucose controls (n=7). 2-DG1LPS completely suppressed locomotor activity in LPS-treated mice (t(13) =
5.766; ###p, 0.0001 vs LPS1saline). F, Blood glucose was suppressed by LPS (main effect: F(1,27) = 60.00; p, 0.0001) and modestly increased by glucose (main effect: F(1,27) = 6.721;
p=0.0152), and post hoc tests showed that LPS1glucose was significantly different to LPS1saline. G, Glucose treatment 1.5 h after LPS provided significant but transient protection against LPS-
induced hypoglycemia. H, CSF (from the same animals) showed a main effect of LPS (F(1,22) = 39.85; p, 0.0001) and a strong main effect of glucose (F(1,22) = 14.57; p=0.0009). LPS1glucose
was significantly different to LPS1saline in post hoc analysis (p, 0.05). Two data points in these analyses represent two pooled samples each (in the saline1glucose and LPS1saline groups where
some CSF samples were too low in volume to be assessed). They have been highlighted as slightly larger, filled symbols. I, CSF lactate levels (same animals) were not altered by the treatments
described. Again, the same samples were pooled for this analysis. In LPS-naive mice, 2-DG on its own does not significantly affect (J) spontaneous activity nor does it: have any effect on (K) blood glu-
cose. Significance levels for Bonferroni post hoc tests: *p, 0.05, **p, 0.01, ***p, 0.001. All data are expressed as mean6 SEM.
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Hypoactivity
Reducing blood glucose can be adaptive for the organism,
depriving infectious agents of a key fuel source, and providing
further glucose can actually increase Listeria monocytogenes-
induced mortality (Wang et al., 2016). Nonetheless, we show, in
the acute phase, that significant LPS-induced decreases in blood
glucose reduce CSF glucose and suppress spontaneous activity.
This is consistent with prior studies showing correlation between
blood glucose and sickness behavior (Carlton and Demas, 2017)
and others showing that insulin-induced hypoglycemia sup-
presses social activity in c57BL/6 mice (Park et al., 2008, 2012).
Here, by directly increasing glucose availability, by applying ex-
ogenous glucose, we prevented LPS-induced suppression of ac-
tivity without reducing IL-1b . Moreover, 2-DG completely
blocked LPS-induced IL-1b secretion, as previously shown for
macrophage IL-1 production (Tannahill et al., 2013) but in also
preventing glucose utilization it further suppressed activity.
Although IL-1 is widely implicated in LPS-induced sickness
behavior, LPS-induced hypoactivity persisted even when IL-1
secretion or action was blocked (IL-1RA, IL-1RI/). Although
IL-1RA protection inhibited LPS-induced hypoglycemia in prior
studies, those effects were partial: 100mg IL-1RA/mouse margin-
ally mitigated hypoglycemia (Del Rey et al., 2006), just as we
observed here. IL-1RA (at 200mg/mouse) completely blocked
effects of 25mg/kg IL-1b (Fig. 1D), which leads to blood levels of
;600pg/ml IL-1b (Skelly et al., 2013), and this IL-1RA dose
should therefore block the effects of LPS-induced IL-1b (;50–
100pg/ml; Teeling et al., 2007; Murray et al., 2011; Skelly et al.,
2013). However, TNF-a also triggers hypoglycemia (Oguri et al.,
2002); thus, IL-1RA can have only a partial effect in limiting
LPS-induced hypoglycemia. Therefore, while IL-1b might be a
key mediator of hypoglycemia at 25mg/kg LPS (Del Rey et al.,
2006), IL-1RA barely limits hypoglycemia with LPS at 250mg/kg
(current study). Ultimately, the ability of glucose to restore activ-
ity in the current experiments reveals the importance of glucose
uptake and use in fueling and regulating spontaneous activity
under LPS-induced inflammation.
The hypothalamus monitors levels of circulating IL-1b
(Matsuwaki et al., 2017) and glucose (López-Gambero et al., 2019)
and coordinates sickness behavior. IL-1b action in the hypothala-
mus is proposed to reprogram the organism to operate at lower cir-
culating glucose levels after LPS (25mg/kg; Del Rey et al., 2006),
and these authors propose that IL-1b increases brain energy me-
tabolism (Del Rey et al., 2016). [18F]-fluorodeoxyglucose (FDG-
PET) experiments show that high-dose LPS (15mg/kg) increased
hypothalamic activity (Wang et al., 2016) but LPS (10mg/kg, i.p.)
has been shown to decrease glucose uptake across multiple cortical
regions (Semmler et al., 2008). If, as reported, IL-1 lowers the set-
point for glucose homeostasis, allowing animals to function effi-
ciently at lower glucose concentrations (Del Rey et al., 2006, 2016;
Besedovsky and Del Rey, 2010), it is not intuitive why transiently
increasing available glucose should rapidly increase spontaneous
activity. Here, we show that administration of glucose raises both
blood and CSF glucose (Fig. 3), and although this “top-up” of glu-
cose provides only temporary and partial increases in available glu-
cose (Fig. 3G; Del Rey et al., 2006), this is sufficient to restore
spontaneous activity and cognition. We therefore propose that
while the hypothalamus might be selectively active during acute
inflammation, to coordinate neuroendocrine responses to the acute
threat, the suppression of spontaneous locomotor activity that is
actually observed may reflect decreased neural activity under-
pinned by decreased available glucose.
Figure 4. Insulin-induced reductions in blood glucose produces acute cognitive dys-
function selectively in mice with prior neurodegeneration. A, ME7 mice have a cogni-
tive vulnerability under LPS treatment (n = 26) that was not present in NBH mice
treated with LPS (n = 21). Saline does not induce cognitive deficits either in NBH
(n = 20) or in ME7 (n = 9) mice. There was an interaction between treatment group
and time (F(12,288) = 5.00; p, 0.0001). Blood glucose (mmol/l; B) and plasma insulin
concentrations (C) in saline-treated or insulin-treated (11.5 IU/kg, i.p.) NBH and ME7
mice. There were similar reductions in blood glucose (B, main effect of insulin,
F(2,20) = 17.11; p, 0.0001) and equivalent insulin concentrations over 180 min in ME7 and
NBH animals (C, main effect of insulin, F(2,28) = 22.86; p, 0.0001). D, T-maze alternation in
ME7 and NBH mice postchallenge with saline or insulin (11 h = 40–160 min; and 13
h = 160–300 min postinsulin). Testing was performed earlier than in LPS-treated mice as in-
sulin produces a more rapid decrease in blood glucose. There was a significant main effect of
insulin (F(3,135) = 7.418; p= 0.0004) and an interaction of ME7 and insulin (F(9,135) = 3.050;
p= 0.0024). ME71insulin-treated mice (n= 12) had significantly lower alternation scores
compared with NBH1saline controls (n= 7) at 1 and 3 h post-injection (NBH1insulin:
n= 9; ME71saline: n= 13). All data expressed as mean and standard error of the mean
(SEM). Significance levels for Bonferroni post hoc tests: *p, 0.05, **p, 0.01,
***p, 0.001.
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The neuroanatomical basis of LPS-
induced suppression of exploratory ac-
tivity is incompletely understood but
correlates with suppression in cFOS in
brain areas associated with positive moti-
vation (Stone et al., 2006) and explora-
tory behavior (Gaykema and Goehler,
2011). LPS triggers norepinephrine (NE)
release in the hypothalamus (Francis et
al., 2001) and lesioning caudal medullary
NE inputs to the hypothalamus blocks
LPS-induced hypoactivity (Gaykema and
Goehler, 2011). Hypoglycemia, hyperinsulin-
emia (Beverly et al., 2001), and 2-DG treat-
ment (Beverly et al., 2000) all induce
hypothalamic NE release, suggesting potential
points of convergence for how inflammation
and impaired glucose metabolism may drive
changes in behavior during sickness.
Whatever the neuroanatomical and
neurotransmitter underpinnings, the cur-
rent data strongly support the idea that
available and usable glucose is a key deter-
minant of LPS-induced suppression of ac-
tivity. This has implications for studies
using peripheral LPS to examine the
neurophysiological and behavioral conse-
quences of systemic infection. Levels of cir-
culating LPS arising from bolus LPS
challenges are higher than in active infec-
tion (Danner et al., 1991). Bolus LPS treat-
ment (4 ng/kg, i.v.) in human volunteers
transiently decreases plasma glucose
(Bloesch et al., 1993) while active infection
typically does not produce hypoglycemia
(Furman et al., 1988). Therefore, although
bolus LPS would appear to have face validity as a model of sys-
temic infection, if key behavioral and neurophysiological changes
induced by LPS in experimental subjects are underpinned by a
physiological change, i.e., hypoglycemia, that rarely occurs dur-
ing active infection, this necessitates a review of the generalizabil-
ity of bolus LPS-induced changes to understand changes during
active infection.
Acute cognitive dysfunction and delirium
Human data suggest that reduced glucose uptake in the medial
temporal lobe associates with impaired performance in hippo-
campal-dependent tasks (Harrison et al., 2014). Remarkably, de-
spite the robust and long lasting reductions in available glucose
shown here, normal LPS-treated mice maintain good working
memory (Fig. 4; Skelly et al., 2019). However, the same decreases
in glucose, caused by LPS or insulin, were sufficient to trigger
dysfunction in animals with prior neurodegeneration. Ex-
ogenously added glucose does not improve cognition in young
rats (Kealy et al., 2017) but enhances cognition in aged rats
(McNay and Gold, 2001), supporting the idea that the same task
may require additional metabolic support in aging/degenerating
brain. We propose that the circuitry underpinning working mem-
ory may, during neurodegeneration, be operating close to thresh-
olds for decompensation and may need to recruit additional
brain areas to maintain this function. The addition of a further
stressor may then be sufficient to unmask underlying vulnerability.
Volunteers exposed to Salmonella typhi vaccination performed
equally to controls on the Stroop test of executive function but
recruited additional areas of the prefrontal and anterior cingu-
late cortex to maintain performance during inflammation
(Harrison et al., 2009). If increased connectivity is required to
maintain performance during inflammation, then inflamma-
tory insults may unmask vulnerability, when evolving neurode-
generation impairs connectivity (Davis et al., 2015). The ME7
model of delirium during dementia has, until now, been an
exemplar for an inflammatory hypersensitivity (Murray et al.,
2012), but these data show that these mice are also more vul-
nerable to “bioenergetic stressors.” Despite equivalent reduc-
tions in blood and CSF glucose, NBH animals are resilient to
hypoglycemia-induced cognitive impairment but ME7 animals
are vulnerable, whether induced by LPS or by insulin.
The brain is a metabolically demanding organ and it may be
adaptive, for survival, to minimize energy use in the brain and
preserve autonomic function at the expense of higher cortical
function. Engel and Romano proposed that delirium is driven by
a failure to meet the brain’s energy requirements, regardless of
the underlying cause (Engel and Romano, 2004). Hypoglycemia
is sufficient, alone, to produce delirium and EEG slowing, and
this is reversed by glucose administration (Engel and Romano,
1944). Small CSF studies support the idea of metabolic distur-
bances during delirium: patients with delirium have elevated
CSF lactate compared with non-delirious Alzheimer’s disease
controls (Caplan et al., 2010) and [18F]FDG-PET studies show
Figure 5. LPS-induced cognitive dysfunction in mice with prior neurodegeneration can be ameliorated by glucose
administration. After 5 h, LPS produced equivalent decrease in glucose concentration in blood (A) and CSF glucose in ME7
(n= 7) and NBH mice (n= 7; B) compared with their respective saline-treated controls (n= 11 and n= 10, respectively).
There were main effects of LPS on blood glucose (F(1,31) = 118.3; p, 0.0001) and on CSF glucose (F(1,22) = 146.5;
p, 0.0001) and also an effect of disease on CSF glucose (F(1,22) = 6.665; p= 0.0170), with ME71saline. NBH1saline
by post hoc analysis. C, There were no differences in CSF lactate levels. D, T-maze alternation in ME7 mice postchallenge
with saline or LPS, co-treated with glucose (2 g/kg) or saline. LPS1saline group (n= 20) showed robust cognitive impair-
ment, but the LPS1glucose group (n= 19) showed significant attenuation. Two-way repeated measures ANOVA showed
a main effect of LPS (F(3,240) = 13.75; p, 0.0001) and an interaction of LPS and glucose (F(12,240) = 3.740; p, 0.0001).
LPS1glucose mice performed significantly better than the LPS1saline group at 5 h postchallenge (##p, 0.01).
Significance levels for Bonferroni post hoc tests: *p, 0.05, **p, 0.01, ***p, 0.001.
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decreased glucose uptake (Haggstrom et al., 2017). The posterior
cingulate cortex, which is associated with attention and arousal,
was particularly affected and disrupting energy metabolism here
could be important in delirium.
Although hypoglycemia in mice is not precisely defined, the
ME7 blood glucose concentrations here remained just above the
clinical threshold for moderate hypoglycemia (3.9mmol/l; Cryer,
2017). Iatrogenic hypoglycemia is common in patients using in-
sulin for diabetes (Cryer, 2002) and is a major cause of emer-
gency department admissions and adverse CNS effects in older
patients (Shehab et al., 2016). Significantly, our ME7 data suggest
that even when blood glucose levels do not fall into classical








(n= 59) p value
Median age, years (range) 84.5 (60–93) 85 (68–95) 0.69 84 (60–101) 86 (64–96) 0.25
Male, n (%) 8 (25) 11 (27.5) 0.81 16 (29) 15 (25) 0.66
Dementia, n (%)a 2 (6.3) 32 (80) ,0.001 Prevalent delirium,
n (%)
8 (15) 32 (54) ,0.001
Independent in activities of daily living,
n (%)b
23 (71.9) 8 (20) ,0.001 39 (71) 7 (12) ,0.001
Living in an institution,
n (%)
3 (9.4) 20 (50) ,0.001 3 (6) 37 (63) ,0.001
APACHE II, median (IQR)c 8 (6.3–9.8) 9 (8–11) 0.004 8 (7–10) 9 (8–10) 0.76
CCI, median (IQR) 1 (0–1.8) 1 (0–2) 0.044 1 (0–2) 1 (0–2) 0.58
ASA score, median (IQR) 2 (2–3) 3 (3–3) ,0.001 3 (2–3) 3 (2–3) 0.33
aBased on consensus in an expert panel.
bDefined as 19 or 20 points on Barthel activities of daily living.
cWithout information on hematocrit and arterial blood gas.
dMann–Whitney test and x 2 tests depending on data distribution.
APACHE II = acute physiology and chronic health evaluation II; ASA = American Society of Anesthesiologists Physical Health Classification; CCI = Charlson Comorbidity Index score; IQR = interquartile range. The columns on
the left (no delirium vs prevalent delirium) contain all patients with prevalent delirium and those who never experienced delirium during their hospital stay. The columns on the right (no dementia vs dementia) contain a
larger number of patients since they include also patients who were subsyndromal for delirium and those who may have experienced delirium at some later point in their hospitalization (but did not have delirium prevalent
at the time of CSF sampling).
Figure 6. Derangement of energy metabolism in human delirium. Metabolite levels in the CSF of hip fracture patients with delirium (n= 40) at the time of CSF sampling compared with
age-matched patients with no delirium at any point of their hospital stay (n= 32). A, Glucose levels in delirium (n= 39, one sample omitted due to a read error) and non-delirium cases were
not significantly different (Mann–Whitney U= 606.5; p= 0.8442). B, Patients with delirium had significantly higher levels of lactate in their CSF compared with controls (U= 442.5;
p= 0.0128). C, Lactate levels in the CSF of hip fracture patients with dementia (n= 59) at the time of CSF sampling compared with age-matched patients with no dementia (n= 55; no signif-
icant difference in CSF lactate U= 1438; p= 0.2954). D, Patients with delirium showed significantly higher pyruvate levels compared with controls (U= 514.5; p= 0.0494), with all levels
below the minimum detectable level (4mmol/l) entered as 50% of this LOD (i.e., 2mmol/ml). E, In addition, pyruvate was detected significantly more often in patients with delirium compared
with patients without delirium at time of CSF sampling (Fisher’s exact test, p= 0.0306). F, The LGR for patients with delirium (n= 39) was significantly higher compared with controls
(U= 399.5; p= 0.0048). G, LPS significantly increased the CSF LGR in both ME7 (n= 7) and NBH mice (n= 7) compared with their respective saline-treated controls (n= 7 and n= 5; F(1,22) =
44.58; p, 0.0001). Significance levels for Mann-Whitney U tests (B, D and F) are annotated by *p, 0.05, **p, 0.01, for Fisher’s exact test (E) by *p, 0.05 and for Bonferroni post-hoc
tests (G) by ***p, 0.001.
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hypoglycemic ranges, these changes have significant deleterious
impacts on brain function in those with prior vulnerability.
Importantly glucose was not lower in the hip fracture patients
studied here (Fig. 6A). Both hypoglycemia and hyperglycemia
increase risk for sepsis-associated encephalopathy (Sonneville et
al., 2017), but hypoglycemia is less common. However, insulin
insensitivity, and impaired glucose uptake, typically accompanies
hyperglycemia-associated delirium. In humans, insulin resistance
occurs on LPS (Agwunobi et al., 2000), infection (Virkamäki et
al., 1992), and surgery (Thorell et al., 1994). Microcirculatory
failure and tissue hypoxia, common in sepsis (Ince and Mik,
2016), may also disrupt glucose oxidation and the elevated lactate
and pyruvate in the current study might indicate a shift from
normal aerobic to anaerobic glycolysis. Although dementia status
is a major risk factor for delirium (Davis et al., 2015), the changes
in lactate and LGR observed are not explained by existing de-
mentia. The data are consistent with previously demonstrated
associations between delirium and increased CSF lactate (Caplan
et al., 2010) and hypoxia (Tahir et al., 2018).
Conclusion
Reduced glucose availability is a major driver of LPS-induced
suppression of spontaneous activity. In animals made vulnerable
by evolving neurodegeneration, this decreased glucose is now
sufficient to trigger acute cognitive dysfunction indicating that
metabolic insufficiency underlies cognitive dysfunction in this
animal model resembling delirium. A disruption of energy me-
tabolism also occurs in delirium triggered by inflammatory
trauma. Together, the findings indicate that acutely disrupted
energy metabolism likely contributes to general behavioral
changes associated with sickness but also to acute neuropsychiat-
ric disorders such as delirium. Systemic inflammation produces
disproportionate brain dysfunction when superimposed on the
vulnerable brain, as is evident during bacterial sepsis and infec-
tions such as SARS-CoV-2 in older people. The appropriate sup-
ply of both oxygen and energy substrates to the brain becomes
especially important in those with existing cognitive vulnerabil-
ity. The current data should focus attention on bioenergetic
mechanisms of acute brain failure during acute illness and hospi-
talization in older adults.
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